Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elanco Animal Health Incorporated (NYSE: ELAN) SEC filings page on Stock Titan provides organized access to the company’s U.S. regulatory disclosures. As an Indiana-incorporated public company in the pharmaceutical preparation manufacturing industry, Elanco files reports with the Securities and Exchange Commission under Commission File Number 001-38661.
Through this page, readers can review current and historical Forms 8-K and, when available, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials. Elanco’s recent Form 8-K filings illustrate the range of topics covered in its SEC disclosures, including quarterly financial results and guidance, restructuring plans and workforce changes, amendments to credit agreements and receivables facilities, and participation in major investor events such as its Investor Day and healthcare conferences.
These filings provide detail on Elanco’s financial condition, capital structure and risk factors, as well as material contracts and strategic initiatives. For example, recent 8-Ks describe the Elanco Ascend restructuring program, expected cost savings, facility changes, and refinancing of term loan facilities, along with updates on leverage targets and cash flow expectations. Other filings outline amendments to securitization and credit agreements that affect the company’s direct financial obligations.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Investors can use the ELAN filings page to monitor new 8-Ks, as well as future 10-K and 10-Q reports, and to track how management’s strategic, financial and operational decisions are reflected in official SEC documents.
Elanco (ELAN) Q2 2025 10-Q highlights:
- Revenue rose 4.8% YoY to $1.24 bn; pet-health up 11% to $643 m, offsetting the divested aqua unit (zero vs $49 m).
- Gross margin held at 57.4% (713 m/1,241 m).
- Operating profile: SG&A climbed 13% to $400 m; R&D up 3% to $92 m; special charges plunged to $1 m from $80 m, driving a swing to positive pretax income of $25 m (-$32 m LY).
- Net income $11 m vs -$50 m; diluted EPS $0.02 vs -$0.10.
- Six-month totals: revenue +1.9% to $2.43 bn; net income $78 m vs -$18 m.
- Cash flow: operating cash +15% to $233 m; FCF negative as capex doubled to $122 m (new HQ).
- Balance sheet: cash $539 m (+$71 m YTD); total debt trimmed to $3.95 bn (ex-lease) from $4.32 bn; however a new $255 m finance lease and $293 m liability tied to royalty sale raise fixed commitments.
- Inventory up 6% YoY to $1.67 bn; accounts receivable +23%.
- Leverage: ~4.1× EBITDA remains high but 89% of debt is fixed; interest expense down 26% YoY.
- Strategic moves: • Closed $295 m royalty monetization with Blackstone (16.1% implied IRR). • HQ lease in Indianapolis (option to buy at $250 m in 2030). • Continued rollout of Zenrelia, Credelio Quattro, Bovaer; EU Zenrelia approval in Jul-25.
- Guidance not updated in filing.
Key takeaways: Return to profitability aided by lower one-offs and interest expense; pet-health momentum strong. Balance-sheet de-risking continues, but inventory build, rising SG&A and new fixed obligations temper the improvement.